Text Size

National Survey on Asthma (SYMPTOMES)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00770250
First received: October 7, 2008
Last updated: November 30, 2010
Last verified: November 2010
History of Changes
  Purpose

To evaluate the concordance of the most frequently used words by the patients and the physicians to express asthma symptoms, according to the patient's level of asthma control.


Condition
Asthma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: A Mirror Assessment of the Words Used By Patients and Physicians to Express Asthma Symptoms, According To the Patient's Level of Asthma Control In General Medicine

Resource links provided by NLM:

MedlinePlus related topics: Asthma
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The concordance of the most frequently used words by the patients and the physicians to express asthma symptoms, according to the patient's level of asthma control. [ Time Frame: Once ] [ Designated as safety issue: No ]

Enrollment: 1704
Study Start Date: September 2008
Study Completion Date: March 2009
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

The first 2 consecutive patients seen during the GP's visit with a diagnosis of persistent asthma

Criteria

Inclusion Criteria:

  • A diagnosis of persistent asthma treated with an inhaled corticosteroid based maintenance treatment for more than 3 months
  • Given his/her consent to participate to the study and who is able to answer the questionnaire in french by him/her-self.

Exclusion Criteria:

  • Patient with a cardiac disease (congestive heart failure, coronary artery disease)
  • Patient with a respiratory disease other than asthma (COPD, sleep apnea syndrome).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00770250

  Show 910 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Alain Castaigne AstraZeneca
  More Information

No publications provided

Responsible Party: Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00770250     History of Changes
Other Study ID Numbers: NIS-RFR-DUM-2008/1
Study First Received: October 7, 2008
Last Updated: November 30, 2010
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
asthma symptoms
words used by patients and physicians
express asthma symptoms

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
 Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on May 16, 2013